– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix...
SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after...
SILVER SPRING, Md., Feb. 03, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 5,520,000 shares of the Company’s Class A common...
First FDA-Cleared Antibiotic-Eluting BioEnvelope Now Available in U.S. for Implantable Pacemakers, Defibrillators, and Neurostimulators SILVER SPRING, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix...
Enter your information and we will be in touch with you.
News Sign Up
Sign up to receive news notifications.
Connect With a Rep
Enter your information and we will be in touch with you.
Learn More Today
Fill out the form below for more information.
Webinar Signup
Sign up to receive webinar notifications.
We use cookies to ensure that we give you the best experience on our website. More information about our site Terms of Use and Privacy Policy provide additional details. Continue on to our site only if you agree with these policies.
